This episode will give you a deeper understanding of the different models that explain the brain mechanisms underlying tinnitus. Dr Will Sedley outlines his own theory, based on predictive processing. We also cover issues like how to develop an objective marker of tinnitus and the thorny topic of whether tinnitus subtypes really exist or not.
This is your chance to learn all about the hearing regeneration treatment FX-322 being developed by Frequency Therapeutics. We spoke with Carl LeBel about the promising results of their Phase 1 trial, the potential benefits for tinnitus, why speech intelligibility should be the primary measure of hearing, and when the drug might reach the market.
A drug to quieten your tinnitus, that’s what Thanos Tzounopoulos, PhD, is working on. The drug targets potassium ion channels in the brain. These channels – or so the theory goes – are compromised in tinnitus patients, thus triggering the neural hyperactivity perceived as tinnitus. In spite of trials and tribulations in getting the drug ready for clinical trials, Thanos is optimistic about his chances for success.
In this special compilation episode, you’ll hear from four people with tinnitus, as well as a researcher and an audiologist, about tinnitus experiences during the Coronavirus crisis. How has the stress of the crisis impacted people’s tinnitus? Can the Coronavirus cause tinnitus to aggravate? What kind of support is available for people struggling during this time?
Do you want to know what clinical evidence says about different treatments for tinnitus? This episode explores the new European Clinical Practice Guidelines for tinnitus, and how they can help patients and doctors; and hopefully inspire more thorough testing of new and existing treatments for tinnitus.